Purpose Ultrahypofractionationed radiation therapy for prostate cancer is increasingly
studied and adopted. The American Association of Physicists in Medicine Working Group on …

Purpose Doses delivered to the urethra have been associated with an increased risk to
develop long-term urinary toxicity in patients undergoing stereotactic body radiotherapy …

Purpose Clinical trials assessing evaluation prostate stereotactic body radiation therapy
(SBRT) have used a wide range of allowed doses to the intraprostatic urethra, but the …

Background To investigate whether the rate of stereotactic body radiation therapy-related
(SBRT-related) genitourinary (GU) toxicity is lower in patients with prostate cancer treated …

Purpose/objectives To report preliminary data on treatment outcome and compliance to
dose-intensified organ sparing SBRT for prostate cancer using a novel electromagnetic …

Purpose This study aimed to report the early toxicity results of a prospective clinical trial of
prostate stereotactic body radiation therapy (SBRT) to the entire prostate with a …

Purpose NCT03253744 was a phase 1 trial to identify the maximum tolerated dose (MTD) of
image-guided, focal, salvage stereotactic body radiation therapy (SBRT) for patients with …

Purpose/objective (s) To report results from our phase II study of stereotactic body
radiotherapy (SBRT) delivering 36 Gy in 4 fractions for patients with localized prostate …

Objective We aimed to report the 2-year results of stereotactic body radiation therapy for
prostate cancer and identify the clinical and dosimetric factors that predict acute …

Introduction Prostate cancer is the fourth most commonly diagnosed cancer among men
worldwide. Various tools are used to manage disease such as conventional radiotherapy …